Genelux Corporation

NASDAQ:GNLX

Biotechnology

Healthcare
$2.24 +2.63%

+$0.08 today

Market cap
$107.66M
Beta
0.55
P/E (TTM)
-3.0
EPS (TTM)
-$0.98
52W Low $2.29High $8.54

Volume 0.80M

Average 0.19M

GNLX Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Genelux CorporationNASDAQ: GNLX

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures growth accelerates

Q1 FY2026 capital expenditures of $921K (cash outflow) rose 2970.0% year over year, ahead of the +422.0% change in trailing-twelve-month capital expenditures. Sequentially, it rose 111.2% from the prior quarter. Over 3 fiscal years it compounded at +181.9% a year.

Context

  • Capital expenditures amounted to 13725.0% of revenue in FY2025, up 8962.5 pp from a year earlier.
  • Capital expenditures grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +2970.0% holds above the trailing-twelve-month pace of +422.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$921K+111.2% QoQ
Last fiscal yearDec 2025
-$1.1M+188.2% YoY
LTMMar 2026
-$1.99M+422.0% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2970.0%——
1 year+188.2%——
3-year CAGR+181.9%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(1.1M) USD
Year-over-year change
-188.2%

Capital Expenditures vs competitors

How GNLX compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +422.0% is the 2nd highest of 8, against a peer median of +19.8%.
  • Capital expenditures amounts to 24862.5% of revenue for GNLX, versus a peer median of 11.5%.
GNLX Competitors
Capital Expenditures for GNLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$6.08M USD—+88.7%—
CLLSCellectis S.A.LTM Mar 2026$2.23M USD-44.0%-1.0%3.3%
GNLXGenelux CorporationLTM Mar 2026$1.99M USD+422.0%+181.9%24862.5%
CADLCandel Therapeutics, Inc.LTM Mar 2026$1.26M USD+10391.7%-23.2%—
ACIUAC Immune S.A.LTM Dec 2025CHF 900.16K CHF+56.3%-11.5%25.2%
LYELLyell Immunopharma, Inc.LTM Mar 2026$623K USD-8.4%-68.2%2009.7%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$496K USD+19.8%+25.1%—
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$432K USD+50.0%-23.9%—
SLNSilence Therapeutics plcLTM Mar 2026$106K USD—-53.4%11.5%
MREOMereo BioPharma Group plcLTM Mar 2026$1.52K USD-99.5%+15.4%0.3%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$4 USD———
Peer median (excluding GNLX) —+19.8%-11.5%11.5%

Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(16.38M)(5.21M)(28.3M)(29.87M)(32.15M)
Depreciation & Amortization895K968K1.02M903K244K
Deferred Income Tax348K0000
Stock-Based Compensation4.27M2.42M5.2M6.07M5.87M
Change in Working Capital4.08M(1.69M)(3.28M)751K(1.05M)
Accounts Receivables00000
Inventory00000
Accounts Payables754K2.31M(2.36M)2.16M(1.21M)
Other Working Capital3.33M(4M)(923K)(1.41M)167K
Other Non-Cash Items196K(56K)5.08M917K1.81M
Operating Cash Flow(6.59M)(3.57M)(20.28M)(21.23M)(25.27M)
Capital Expenditures0(49K)(1.03M)(381K)(1.1M)
Acquisitions (Net)00000
Purchases of Investments00(13.7M)(29M)(18.26M)
Sales of Investments00021.25M31.5M
Other Investing Activities00000
Investing Cash Flow0(49K)(14.72M)(8.13M)12.14M
Debt Repayment(558K)970K215K00
Common Stock Issued143K120K39.65M27.82M9.9M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities145K(1.45M)4.16M688K0
Financing Cash Flow(270K)(478K)44.02M28.51M9.9M
Effect of Forex Changes00000
Net Change in Cash(6.86M)(4.1M)9.02M(853K)(3.23M)
Free Cash Flow(6.59M)(3.62M)(21.3M)(21.61M)(26.37M)

Genelux Corporation

NASDAQ:GNLX

Intrinsic Alpha fair value

Locked

Current Price

$2.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.